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ABSTRACT
Cytomegalovirus  (CMV)  is  one  of  the  most  important  viral  pathogen  in  solid  organ 
transplant (SOT) recipients, with heart and lung transplant patients being at considerably 
high  risk  for  CMV  direct  and  indirect  effects.  Prevention  strategies  have  resulted  in 
significant  reduction  in  disease and CMV related  morbidity  and mortality.  Few studies 
reported a lower incidence of CMV infections in solid organ transplant recipients treated 
with immunosuppressive protocols including the mTOR inhibitor everolimus (EVR).
Purpose. The  aim  of  the  current  study  was  to  evaluate  the  impact  of  EVR-based 
immunosuppressive  regimens  on  the  occurrence  and  kinetics  of  CMV  infection  in  a 
population of lung transplant recipients, at both systemic and pulmonary level. Thirty-two 
lung transplants (LT) were investigated; eighteen were on EVR-based immunosuppressive 
regimens.  CMV  events  occurring  in  the  first  two  years  post-transplantation  at  both 
systemic and pulmonary levels were reported.
Principal results. No differences were reported in CMV viraemiae occurrence at both one- 
and  two-year  follow  up  between  patients  undergoing  EVR-based  and  EVR-free 
immunosuppressive  regimens.  Considering  CMV  episodes  at  pulmonary  levels,  as 
determined  by  routinely  performed  broncho-alveolar  lavages  (BAL),  during  EVR-
administration the patients experienced significantly fewer episodes of high-load CMV (as 
defined  by  viral  loads  ≥  105 copies/mL)  than  during  EVR-free  immunosuppressive 
regimens.
Major  conclusion. EVR-based  immunosuppressive  regimens  in  lung  transplantation 
settings appear to be associated to lower incidence of clinically relevant CMV episodes at  
pulmonary levels, striking the possibility of extending the use of EVR to such a group of 
transplant recipients.
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1.  INTRODUCTION
Cytomegalovirus (CMV) is a ubiquitous β-herpesvirus that establishes lifelong latency in 
host  tissues  following  primary  infection.  The  occurrence  of  CMV  primary  infection  in 
seronegative  individuals  or  the  capability  of  viral  reactivation  in  immunocompromised 
conditions  makes  CMV  one  of  the  most  important  viral  pathogens  in  solid  organ 
transplantation  (SOT),  with  incidence of  infection/disease ranging from 8% up to  50% 
depending on the transplanted organ.  Heart  and lung transplant  (LT)  recipients are at 
particularly high risk for CMV direct and indirect effects and evidence indicates that related 
morbidity and mortality are greater in LT recipients than in other SOT, as lung is a major 
site for CMV latency and recurrence. . Direct effects of CMV infection can manifest as 
systemic  or  organ-specific  disease,  whereas  indirect  effects  reflect  altered  immune 
responses associated with infection, resulting in increased incidence of graft dysfunction,  
acute and chronic rejection, and opportunistic infections.  (Fishman et al. 2007). Acute and 
chronic graft rejection are relevant determinants of morbidity and mortality, particularly in 
the first two years post-transplantation and several studies have reported an association 
between  CMV  infections  and  organ  rejection,  with  the  CMV  donor/recipient  (D/R) 
serological matching D+/R- being at the highest risk, although the underlying mechanisms 
are still unclear. .
Prevention  strategies  may result  in  significant  reduction  in  CMV-related  morbidity  and 
mortality in SOT recipients. Two main prevention strategies are commonly used: universal 
prophylaxis  with  administration  of  antiviral  agents  in  all  the  patients  and  pre-emptive 
therapy based on virological  monitoring  (usually  by evaluation  of  CMV-DNA on whole 
blood) and antiviral administration in the presence of laboratory evidence of infection, with 
relevant variations in clinical practice in different transplant centers.   .
4
Considering  immunosuppressive  protocols,  few  studies  on  heart  and  kidney 
transplantation  reported  a  lower  incidence  of  CMV  infections  in  patients  treated  with  
regimens  including  everolimus  (EVR),  a  proliferation  signal  inhibitor  (PSI)/mammalian 
target of rapamycin (mTOR). mTOR inhibitors act by leading to inhibition of translational 
processes depending on mTORC1 activity, preventing cell-cycle progression from G1 to S-
phase  in  T-cells;  moreover,  a  potential  antiviral  effect  through  interruption  of  certain 
mTORC pathways or immune deviation has been evidenced. (Boffini et al. 2009)        . The 
antiproliferative effect of  EVR may represent a therapeutic option in immunosuppressive 
protocols of LT by reducing both the risk of acute rejection and the process of progressive 
fibrosis  that  determines  chronic  graft  rejection.  However,  few  data  on  EVR-based 
immunosuppression  in  LT  are  available  and  the  effectiveness  in  conferring  protection 
towards CMV infection, along with the specific indications and the most adequate time for  
its introduction or dosing, are still controversial. 
The  aim  of  this  study  was  to  prospectively  evaluate  the  impact  of  EVR-based 
immunosuppressive regimens on the occurrence and kinetics of CMV infection and CMV-
related events at systemic and pulmonary level, in a population of LT recipients. 
2. MATERIALS AND METHODS
Thirty-two  consecutive  patients  undergoing LT between 2007 and 2012 (mean age at 
transplantation ± SD, 49.7 ± 16.2 years; range 17-68.7), with at least one-year follow up,  
were  prospectively  studied.  The  main  demographic  and  clinical  features  of  the  study 
population  are  summarized  in  Table  1.  Informed  consent  was  obtained  from  all  the 
patients. The study population was divided in two groups: 1) 18 patients treated with EVR-
based immunosuppressive regimens at different times post-transplantation (EVR-group); 
2) 14 patients treated with EVR-free immunosuppressive protocols for all the study period 
(no-EVR-group). The EVR-group included two patients receiving EVR de novo within one 
5
month  post-transplantation  (one  for  gastric  intolerance  to  mycophenolate  mofetil,  in 
association with severe relapsing neutropenia flares following introduction of azathioprine; 
one due to history of breast cancer), four within 6 months, and five within 12 months; four 
and three patients switched to EVR-based protocols in the second and third year post-
transplantation, respectively (mean time at EVR introduction, 14.5 ± 10.9 months). In 17 
out of 18 patients EVR was administered for at least six months. EVR was administered 
twice  daily,  with  a  goal  trough level  of  3  to  8  ng/dL.  The main  indications leading to 
switching  to  EVR maintenance  immunosuppressant  are  listed  in  Table  2.  In  the  EVR 
group,  five  patients  were  at  high  risk  for  CMV infections  (as  identified  by  serological 
matching D+/R-)  and began EVR-administration at  9,  12,  15,  21 and 33 months  post 
transplantation, respectively.
According to our Centre’s practice, LT recipients were submitted to surveillance visits, 
including  bronchoscopy  with  bronchoalveolar  lavage  (BAL),  transbronchial  biopsy  and 
whole blood draws, at 1, 3, 6, 9, and 12 months post-transplantation; further visits were 
performed at 18 and 24 months post-transplantation, and then annually, as well as in the 
presence  of  clinical  signs  and/or  symptoms  and/or  rejection.  Further  whole  blood 
specimens were collected for CMV-DNA quantitation with trimestral periodicity. 
All LT recipients received a universal, prolonged and combined anti-viral prophylaxis for 
CMV consisting in the administration of ganciclovir or valganciclovir (450 mg bid) from day 
21 for 3 weeks associated to CMV-immunoglobulins (Cytotect Biotest™) at days 1, 4, 8, 
15, and 30 (1.5 ml/kg body weight) and monthly up to 1 year post-transplantation (1 ml/kg 
body weight), irrespective of CMV serostatus. . Furthermore, all patients received long-
term general antiviral prophylaxis with acyclovir 200 mg bid. Ganciclovir or valganciclovir  
were further administered based on clinical judgements and/or in case of CMV-DNA viral 
loads  on  whole  blood  and/or  BAL  greater  than  104 copies/mL.  Long-term 
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immunosuppression was with cyclosporine A or tacrolimus (in patients with cystic fibrosis 
as  underlying  disease),  mycophenolate  mofetil,  and  prednisone  (to  be  tapered  or 
discontinued).  In three patients with  cystic  fibrosis,  also azathioprine was administered 
(one from the EVR-group, two from no-EVR). Allograft rejection was histopathologically 
diagnosed and graded on trans-bronchial biopsy specimens, according to the International  
Society for Heart and Lung transplantation Working Formulation .
For CMV-DNA quantitation on whole blood and BAL samples, a real time PCR assay was 
used. Total DNA was extracted on the automated QIAsymphony® system (Qiagen, Hilden, 
Germany), according to the manufacturer’s instruction. A commercially available real time 
PCR assay amplifying a region of the exon 4 of MIEA (major immediate early antigen) of 
CMV  (Q-CMV  Real  Time  Complete  Kit,  Nanogen  Advanced  Diagnostic,  Italy)  was 
performed on a 7500 Real-Time thermo-cycler system (Applied Biosystems, USA). Briefly,  
20 μL of DNA extracted from 200 μL of whole blood or 1 mL of BAL fluid (obtained from 
the firstly-recovered 10-mL aliquot from a volume of 150 mL saline solution injected for 
BAL diagnostic procedure) were added to 20 μL of mastermix,  and amplified following 
manufacturer’s  instruction.  The  occurrence  of  CMV-DNA  in  whole  blood  and  BAL 
specimens during the first two years post-transplantation was compared in EVR- versus 
no-EVR-treated LT recipients. The occurrence of CMV events was also stratified according 
to donor/recipient CMV serostatus.
Statistical analysis was performed using Student’s t-test, χ2-test and Fisher’s exact test, as 
appropriate, on GraphPad Prism version 4.00 software. A p-value <0.05 was considered 
statistically significant.
3. RESULTS
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The EVR group included 13 patients at low risk for CMV reactivations at baseline (i.e. 
serological matching status D+R+, D-R+, D-R-: 13/18, 72.2%), and five patients at high 
risk (D+/R-, 27.8%); all the patients in the no-EVR-group turned to be at low risk (14/14, 
100%), p>0.05. Neither differences in age (mean age at transplantation, 54.2 vs 43.9 yrs,  
p>0.05), nor gender distribution (male to female ratio, 13/5, and 9/5, p>0.05) were reported 
between the two groups. The immunosuppressive regimens adopted are reported in table 
2.  Only two patients received EVR within  one month post  transplantation,  with  3-year  
follow  up  data  available.  Given  the  small  number  of  patients  undergoing  very  early 
administration of EVR, and to missing at follow up, data for CMV replication were analyzed 
referring to events globally occurring in the first and second year post transplantation. In 
Figure 1 is graphically reported the distribution of CMV events in blood (panel A) and at 
pulmonary  levels  (panel  B,  global  incidence;  panel  C,  CMV-DNA  viral  loads  ≥105 
copies/mL BAL) per single patient,  in function of time (x-axis)  and of concurrent EVR-
including immunosuppressive regimens (fixed lines, EVR-based regimens; dot-lines, EVR-
free regimens). Occurrence of CMV episode is depicted as black square/circle, and the 
absence as white. CMV events were analyzed by Fisher’s exact test.
3.1 CMV events at pulmonary level
Globally,  29 out of 32 patients (90.6%) experienced at least one episode of pulmonary 
CMV infection during the first year post transplantation (as defined by occurrence of CMV-
DNA on BAL), with a cumulative incidence of pulmonary CMV episodes of 48.7% (the first 
episode occurring at a median of 3 months post transplantation). Three patients (9.4%) 
persisted free of any CMV reactivation at two years follow up, when a global rate of CMV 
episodes of 47.8% was observed. These latter patients were on EVR-free regimens for the 
entire observation period. The distribution of CMV episodes in BAL specimens is reported 
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in  Table  3,  at  both  1-  and  2-year  follow  up,  according  to  EVR  inclusion  in  the 
immunosuppressive regimens.
Overall, 13 patients experienced high load CMV positive BAL (as defined by CMV loads ≥ 
105  copies/mL),  with  18 episodes in the first  year  and 2 episodes in the second year.  
Detailed analyses of pulmonary events showed no occurrence of high-load CMV-positive  
BAL specimens during treatment with EVR in the first year post transplantation (Fisher’s 
exact test, p=0.0247). The strength of the association was confirmed at two-year follow up, 
when 20 out of 209 BAL determinations available for analysis (9.6%) reported high-load 
CMV  results,  with  persistent  absence  of  high-load  determinations  in  the  EVR-group 
(Fisher’s exact test,  p=0.0049). For EVR therapy data analyses, a minimum of 4-week 
administration  course was  necessarily  required  for  an  episode to  be  addressed to  as 
occurring during EVR treatment itself. However, when excluding the high risk group (i.e. 5 
patients  with  pre-transplant  CMV  D+R-  serostatus),  the  strength  of  the  correlation 
weakened in significance, at both one (p=0.1216) and two-year follow up (p=0.0715) (Data 
reported  in  Table  3).  It  has  to  be  pointed  that  even  during  the  second  year  post  
transplantation, no patient experienced high-load CMV episodes in BAL concomitant to 
EVR-based immunosuppression (the highest being 12700 copies/mL in the first year and 
11646 copies/mL in the second year). In the no-EVR group the highest CMV load was 
1641550 copies/mL at 3-month determination in a D+/R- subject experiencing a primary 
CMV infection. When comparing mean CMV viral loads during EVR administration versus 
no-EVR regimens, no difference was found between the two groups at both 1- and 2-year  
follow up (Table 5). The time course of CMV episodes in BAL in function of EVR-including 
immunosuppressive regimens is reported in Figure 1.
3.2 CMV episodes at systemic level
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Twenty-three patients (71.9%) experienced at least one episode of CMV viraemia within 
the first year post transplantation, 25 (78.1%) within the first two years, with a cumulative 
incidence  of  viraemic  episodes  of  30.6%  and  24.6%  at  1-  and  2-year  follow  up, 
respectively (median time for first occurrence, 3 months). No difference was found when 
comparing  the  cumulative  incidence  rates  of  viraemic  episodes  during  EVR-based 
immunosuppressive regimens administration versus non-EVR, at both 1- and 2-year follow 
up (p>0.05). In Table 4 is reported the distribution of the CMV episodes in blood on the 
basis of  EVR administration at both 1- and 2-year  follow up. The time course of EVR 
administration together with CMV determinations in blood are depicted in Figure 1. Neither 
in the first nor in the second year post transplantation did the CMV viral loads significantly 
differ during EVR-based immunosuppression versus non-EVR (Table 5).
All five patients at greater risk for CMV infection (D+R- at pre-transplant) exhibited CMV-
related  events  within  six  months  post  transplantation,  with  positive  detections  at  both 
systemic  and pulmonary levels  (reported peak levels:  633155 copies/mL in  blood and 
1641550 copies/mL in BAL). Among them, only two patients received EVR within the first  
year  (both  starting  at  9  months  post  transplantation),  hampering  the  possibility  to 
investigate the potential of EVR on CMV replication at a very early stage. 
3.3 Graft rejection
Graft  rejection  was  histopathologically  monitored  on  trans-bronchial  biopsies  routinely 
performed at months 1, 3, 6, 9, 12, 18, 24 post-transplantation, and on clinical suspicion.  
Twenty-four (75%) patients out of 32 experienced at least one episode of acute rejection  
within the first year (19 at grades 1-2, 5 at grades 3-4), and 6 (24%) out of the 25 patients  
with available determinations in the second year (5 patients grade 1-2, 1 patient at grade 
3). Data are summarized in Table 6. Focusing on the first year post-transplantation, out of  
8 patients who underwent EVR-including regimens for a minimum of three months, no 
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case of A3 and A4 rejection was reported, in contrast to 4 and one patients experiencing 
the  reported  rejection  intensities  during  non-EVR  courses,  without  reaching  statistical  
significance.
4. DISCUSSION
CMV infection, with its direct and indirect effects, is responsible for significant morbidity 
and mortality in lung post-transplantation period, thus justifying investigations on effective  
prevention strategies. The development of both novel laboratory and clinical markers to 
identify patients at greatest risk for CMV disease and therapeutic strategies to prevent  
CMV burden  are  rising  as  matters  of  great  concern  in  clinical  setting.  Some  studies 
suggested how the introduction of EVR in the immunosuppressive regimens could lower 
the incidence of CMV infection (specifically,  in heart and kidney transplant recipients) ,  
even though the benefit of mTOR inhibitors observed in the de novo immunosuppressive 
settings may not  be apparent  in  patients switching to  mTOR inhibitors following initial  
different immunosuppressive protocols.   
The present study aimed to seek the benefit of using EVR-including immunosuppressive 
regimens on the course of CMV infections in lung transplant patients. At our knowledge, 
no study currently investigated the issue of EVR and CMV risk assessment in LT, whereas 
data  are  available  as  regards  kidney and  heart  transplantation,  showing  the  potential 
benefit in the prevention of CMV-related events. . A recent metanalysis of 11 randomized 
trials comparing immunosuppressive regimens containing either EVR or sirolimus versus 
non-mTOR-regimens pointed out that the incidence of acute rejection and CMV infection 
were  reduced  when  the  two  drugs  were  used  instead  of  either  azathioprine  or 
mycophenolate  mofetil  .  Notably,  few  studies  demonstrated  significantly  fewer  CMV 
infections at both 12 and 24 months post cardiac transplantation, a difference that was 
also present in the high-risk D+/R- subgroup.  . These observations have been confirmed 
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in 2012 by Gurk-Turner  et al., who reported higher rates of CMV infections in heart and 
kidney transplants receiving EVR-free immunomodulations than those EVR-based. .
In the present study no difference was found as regards the cumulative incidence rates of  
CMV viraemic episodes in EVR-based immunosuppressive regimens versus non-EVR, at 
both 1- and 2-year-follow up. Interestingly, patients receiving EVR-based regimens had a 
significantly lower cumulative incidence of overall high-load CMV pulmonary infections (as 
defined by CMV viral loads in BAL ≥105 copies/mL), as indicated by the absence of high-
viral load episodes at the end of both the first and the second year post-transplantation, in 
comparison to EVR-free recipients (p<0.05 and p<0.005, respectively). Since no difference 
was observed in the incidence rates of low-level CMV viral loads in the EVR-based group, 
it’s intriguing to speculate that the anti-viral activity of the drug only potentially manifest in a 
background of highly-active viral milieu, likely sustained by immunosuppressive strategies. 
This is pertinent with the notion reporting the lung as a site of major latency for CMV. 
Even though only two out of five D+/R- patients at high-risk for CMV infection received 
EVR in  the first  year  (both starting at  9  months post  transplantation)  -  precluding the 
possibility  to  draw conclusions on everolimus implications  during  the  most  challenging 
period for CMV primary infections - it has to be pointed that none of them showed high-
viral load infections at both pulmonary or systemic level concomitant to EVR administration 
at  two-year  follow  up.  This  observation  is  consistent  with  previous  reports  on  lower 
proportions  of  D+R-  heart-transplant  patients  with  CMV  infections  when  receiving 
everolimus as immunosuppressant (Hill et al. 2007). 
The findings reported in the present observational study are consistent with  previously 
published results showing reductions in the incidence of CMV infection in EVR-treated 
kidney and heart transplants   . The biological mechanisms behind the association of EVR 
administration and lower CMV manifestations are far from clear. Nonetheless, some data 
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suggest  a  compelling  role  of  mTOR  inhibitors  in  the  modulation  of  CMV  replication 
process,  likely  due  to  the  negative  interference  with  CMV  translation  mechanisms 
operated by EVR-mediated blockade of mTOR-dependent “proliferation” pathways, as well  
as by its influence on the immune-mediated responses, as mTOR inhibitors have recently  
been shown to enhance memory T-cell formation and effectiveness of virus-specific CD8+ 
T-cells, while inhibiting immune activity in response to graft transplantation.  . The lower 
incidence  of  CMV  episodes  during  EVR-regimens  does  not  appear  to  be  related  to  
potential bias due to relatively less potent immunosuppression in the EVR-group, since no 
case  of  high  intensity  acute  rejection  (A3  and  A4  stage)  was  reported  in  this  group, 
whereas  5  patients  reported  A3  and  A4  acute  rejection  during  non-EVR 
immunosuppression in the first year post transplantation. Even though suffering from small 
sample size, it  is likely that the reduced CMV infection rates in the lung are linked to  
improved long-term organ survival.
In conclusion, data from the present study seem to confirm the decrease in CMV events in  
transplant patients undergoing EVR-based immunosuppressive regimens, also including 
LT recipients. These preliminary data could justify additional studies and long-term follow 
up of EVR-based immunosuppression that are specifically designed to evaluate critical 
CMV endpoints.
GLOSSARY
EVR, everolimus; SOT, solid organ transplant; CMV, cytomegalovirus; LT, lung transplant.
LEGENDS TO FIGURE AND TABLES
Table 1. General characteristics of the study population.
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a Including one patient with combined liver-lung transplantation belonging to the no-EVR 
group.
Table 2. Main results.
a Only episodes occurring in the first two years post transplantation during the very 
administration of everolimus were considered.
b Excluding one patient whose immunosuppressive regimen included everolimus ab 
initio.
c Including one patient undergoing EVR-based immunosuppression since the trans-
plantation, uninterruptedly for the entire observation period. In the upper part of the 
cell are reported the EVR-free  immunosuppressive regimens adopted (both in the 
EVR- and no-EVR group); in the lower part, the EVR-based regimens.
Table 3.
Distribution of CMV episodes in BAL specimens for the indicated observation periods and 
on  the  basis  of  concomitant  EVR administration.  CMV occurrences  are  compared  by 
Fisher's exact test. For each time and viral load group, CMV occurrences in patients at low 
risk for CMV reactivation (i.e. excluding pretransplant CMV D+R- serostatus) are reported 
in Italics. The definition "high viral loads" refers to ≥105/mL, as reported in the text. VL, viral 
load; IS, immunosuppression.
Table 4.
Distribution of CMV episodes in blood for the indicated observation periods and on the 
basis of EVR administration, irrespective of viral load values. For each period and viral  
load group, CMV occurrences in patients at low risk for CMV reactivation (i.e. excluding 
those  presenting  a  pre-transplant  CMV D+R-  serostatus)  are  reported  in  Italics.  CMV 
occurrences are compared by Fisher's exact test. IS, immunosuppression.
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Table 5.
Distribution of CMV episodes and viral load means in BAL and in blood for the observation  
periods  indicated in  the  text.  Student's  t-test  was  used for  comparison of  means.  IS, 
immunosuppression.
Table 6.
Distribution of patients on the basis of  histopathologically confirmed acute rejection on 
TBB. In right columns are reported the numbers of patients with the indicated maximum 
intensity-level AR episodes, stratified by concomitant EVR administration; when different 
intensity-level episodes were detected in the same time period post transplant, only the 
highest was reported. Data were analyzed by Fisher's exact test.
a In the first year post transplant, two patients experienced graft acute rejection during both 
EVR-free  and  EVR-based  regimens  (A3  and  A2  maximum  intensity  during  EVR-free 
regimens,  respectively,  followed  by  A1-rejection  during  EVR-based);  three  patients, 
considering two-year follow up.
b The reported n=31 is due to one patient undergoing EVR-based immunosuppression 
uninterruptedly during the 24-month follow up.
AR, acute rejection.
Figure  1. Incidence  of  CMV events  over  time  in  blood  (panel  A).  Incidence  of  CMV 
episodes over time in BAL: global incidence (panel B), and high-values (viral loads ≥ 10 5 
copies/mL, panel C). Fixed lines, EVR-based regimens; dot-lines, EVR-free regimens. The 
identification codes of the patients are reported on the y-axes. Red dots: CMV positive 
events; white dots, CMV negative results (in peripheral blood or BAL).
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Features Study population EVR group no-EVR group
Total N = 32 N = 18 N = 14
Age at transplantation 
mean ± SD (range), years 
49.7 ± 16.2
(17-68.7)
52.8 ± 14.8
(24.2-68.3)
47.4 ± 17.0
(17-68.7)
  M/F 22/10 13/5 9/5
Type of transplant
  Bilateral a 17 (53.1%) 11 6
  Monolateral 15 (46.9%) 7 8
Donor/Recipient CMV matching, N (%)
  Low risk  (D+/R+ and D- /R+) 26 (81.3%) 12 (66.7) 14 (100)
                (D-/R-) 1 (3.1%) 1 (5.6) 0
  High risk (D+/R-) 5 (15.6%) 5 (27.7) 0
Table 1
General characteristics of the study population.
a Including one patient with combined liver-lung transplantation belonging to the no-EVR group.
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Features Study population EVR group No-EVR group
Number of patients (%) Total N = 32 N = 18 N = 14
CMV positive DNAemia 10/17 (58.8)a 3 (21.4%)
CMV infected BALs 16/17 (94.1%)a 11 (78.6%)
Indications to everolimus switchb NA NA
renal failure 2 (6.3)
appearance or progression of 
chronic rejection or BOS 4 (12.5)
chronic lung graft dysfunction 
(CLGD, including bronchial 
stenosis) 7 (21.9)
repeated CMV or other 
Herpesviridae infections 2 (6.3)
intolerance of other 
immunosuppressors (neurotoxicity, 
leukopenia, gastro-intestinal 
disorders, dermatosis) 2 (6.3)
immunosuppressive regimensc
CSA+MMF 9 (28.1) 7 (38.9) 2 (14.3)
CSA+MMF → TAC+MMF 9 (28.1) 6 (33.3) 3 (21.4)
TAC+MMF 10 (31.3) 3 (16.7) 7 (50)
TAC+AZA 1 (3.1) 1 (5.6) 0
TAC+AZA → TAC+MMF 1 (3.1) 0 1 (7.1)
TAC+MMF → TAC+AZA 1 (3.1) 0 1 (7.1)
CSA+EVR 6 (18.8) 6 (33.3) NA
TAC+EVR 12 (37.5) 12 (66.7) NA
Transplant-related mortality 
(years post tx)
1 2 (6.3%) 2 (11.1) 0
2 0
3 2 (6.3%) 2 (11.1) 0
4 0
5 1 (3.1%) 1 (5.6) 0
6 3 (9.4%) 0 3 (21.4)
Table 2
Main results.
a Only episodes occurring in the first two years post transplantation during the very 
administration of everolimus were considered.
b Excluding one patient whose immunosuppressive regimen included everolimus ab initio.
c Including one patient undergoing EVR-based immunosuppression since the transplantation,
uninterruptedly for the entire observation period. In the upper part of the cell are reported the EVR-free
immunosuppressive regimens adopted (both in the EVR- and no-EVR group); in the lower part,
the EVR-based regimens.
BOS, bronchiolitis obliterans syndrome; MMF, mycophenolate mofetil; TAC, tacrolimus;
AZA, azathioprine; EVR, everolimus; CSA, cyclosporin A.
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Time post 
transplant
Study population 
(N=32)
Patients with at 
least one CMV 
positive BAL
Evaluable BAL 
determinations 
Number of CMV positive 
BAL samples (irrespective 
of IS regimens)
Concomitant with 
EVR-based 
regimens
During EVR-free 
regimens p
1st year, 
any VL 32 29 (90.6%) 156 76 (48.7%) 18 (11.5%) 58 (37.2%) 0.3160
excluding 
CMV D+R- 27 24 (88.9%) 131 58 (44.3%) 15 (11.5%) 43 (32.8%) 0.1995
1st year, 
high VLs only 32 13 (40.6%) 156 18 (11.5%) 0 18 (11.5%) 0.0247
excluding 
CMV D+R- 27 9 (33.3%) 131 10 (7.6%) 0 10 (7.6%) 0.1216
1st + 2nd year,
any VL 32 29 (90.6%) 209 100 (47.8%) 25 (11.9%) 75 (35.9%) 0.6277
excluding CMV 
D+R- 27 24 (88.9%) 175 76 (43.4%) 18 (10.3%) 58 (33.1%) 0.5850
1st + 2nd year,
high VLs only 32 13 (40.6%) 209 20 (9.6%) 0 20 (9.6%) 0.0049
excluding 
CMV D+R- 27 9 (33.3%) 175 12 (6.9%) 0 12 (6.9%) 0.0715
Table 3
Pulmonary CMV infections
Distribution of CMV episodes in BAL specimens for the indicated observation periods and on the basis of concomitant EVR administration. CMV 
occurrences are compared by Fisher's exact test. For each time and viral load group, CMV occurrences in patients at low risk for CMV reactivation (i.e. 
excluding pretransplant CMV D+R- serostatus) are reported in Italics. The definition "high viral loads" refers to ≥105/mL, as reported in the text. VL, viral 
load; IS, immunosuppression.
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Time post 
transplant
Study 
population 
(n=32)
Patients with at 
least one CMV 
blood episode
evaluable 
blood 
determinations
Number of CMV 
episodes, irrespective of 
IS type
concomitant with 
EVR-based 
regimens
during EVR-
free regimens p
1st year 32 23 (71.9%) 157 48 (30.6%) 11 (7%) 37 (23.6%) 0.5196
excluding 
CMV D+R- 
recipients
27 18 (66.7%) 132 35 (26.5%) 9 (6.8%) 26 (19.7%) 0.4634
1st + 2nd year 32 25 (78.1%) 260 64 (24.6%) 21 (8.1%) 43 (16.5%) 0.1959
excluding 
CMV D+R- 
recipients
27 20 (74.1%) 217 48 (22.1%) 16 (7.4%) 32 (14.7%) 0.0829
Table 4
Distribution of CMV episodes in blood for the indicated observation periods and on the basis of EVR administration, irrespective of viral 
load values. For each period and viral load group, CMV occurrences in patients at low risk for CMV reactivation (i.e. excluding those 
presenting a pre-transplant CMV D+R- serostatus) are reported in Italics. CMV occurrences are compared by Fisher's exact test. IS, 
immunosuppression.
CMV infections in blood
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Number of CMV 
episodes in BAL 
samples, 
irrespective of IS 
type
Number of CMV 
episodes in 
blood samples, 
irrespective of 
IS type
Months post 
transplant N of patients
concomitant with 
EVR-based 
regimens
during EVR-free 
regimens p-value
concomitant with 
EVR-based 
regimens
during EVR-free 
regimens p-value
1st year 32 76 5071 ± 953.5 (1400-12700)
156036 ± 47223 
(1500-1641550) 0.0804 48/157 (30.6%)
2973 ± 896.3 
(1500-11400)
190000 ± 160500 
(600-5935100) 0.5315
excluding 
CMV D+R- 
recipients
27 58 4999 ± 1069 (1400-12700)
68293 ± 22794 
(1500-658904) 0.1086 35/132 (26.5%)
3100 ± 1093 
(1500-11400)
237400 ± 227900 
(600-5935100) 0.5533
1st + 2nd year 32 100 5205 ± 812.1 (1400-12700)
126830 ± 37302 
(1500-1641550) 0.0636 64/260 (24.6%)
2271 ± 487.3 
(1500-11400)
163700 ± 138200 
(600-5935100 ) 0.4194
excluding 
CMV D+R- 
recipients
27 76 5129 ± 984.7 (1400-12700
58386 ± 
18119(1500-
658904)
0.1074 48/217 (22.1%) 2400 ± 632.5 (1500-11400)
193200 ± 185200 
(600-5935100) 0.4725
Table 5
blood CMV viral loads
mean ± SEM (range)
Study 
population
BAL CMV viral loads
mean ± SEM (range)
Distribution of CMV episodes and viral load means in BAL and in blood for the observation periods indicated in the text. Student's t-test was used for comparison of 
means. IS, immunosuppression.
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Patients with 
available data
Time post 
transplant
concomitant 
with EVR-
based 
regimens
during EVR-
free 
regimens
EVR no-EVR p EVR no-EVR p EVR no-EVR p EVR no-EVR p
1st year 32 24a (75%) 4 22 3/8 6/31b 0.3548 1/8 11/31 0.3938 0/8 4/31 0.5628 0/8 1/31 1.0
1st + 2nd year 32 25a (78.1) 6 22 4/12 6/31b 0.4267 2/12 10/31 0.4563 0/12 5/31 0.2996 0/12 1/31 1.0
Acute rejection intensity
A3 A4
Patients with histopathologically 
confirmed AR episodes
A1 A2
Distribution of patients on the basis of histopathologically confirmed acute rejection on TBB. In right columns are reported the 
numbers of patients with the indicated maximum intensity-level AR episodes, stratified by concomitant EVR-administration; 
when different intensity-level episodes were detected in the same time period post transplant, only the highest was reported. 
Data are analyzed by Fisher's exact test.
a In the first year post transplant, two patients experienced graft acute rejection during both EVR-free and EVR-based 
regimens (A3 and A2 maximum intensity during EVR-free regimens, respectively, followed by A1-rejection during EVR-
based); three patients, considering two-year follow up.
b The reported n=31 is due to one patient undergoing EVR-based immunosuppression uninterruptedly during the 24-month 
follow up.
Table 6
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Figure 1
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